First, the current study (like several previous studies) used genetic ablation of GPX4 as the approach to inhibit GPX4 in tumours, because currently there is no good GPX4 inhibitor available that is suitable for in vivo treatment. The gene discussed is GPX4; the disease is neoplasm.